Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI

European Neuropsychopharmacology

Volumn 22, Issue 8, 2012, Pages 537-545

  Schouw, M L J ^a   Gevers, S ^a   Caan, M W A ^a   Majoie, C B L M ^a   Booij, J ^a   Nederveen, A J ^a   Reneman, L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

MDMA; Neurotoxicity; Pharmacological MRI; Serotonin; SPECT

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CITALOPRAM; IOMETOPANE I 123; SEROTONIN; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; BRAIN BLOOD FLOW; BRAIN MAPPING; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIZZINESS; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE RECONSTRUCTION; IMPULSIVENESS; MALE; METHAMPHETAMINE DEPENDENCE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PRIORITY JOURNAL; RECEPTOR BINDING; SEROTONERGIC DYSFUNCTION; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIN LABELING;

ADULT; AFFECT; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; CROSS-SECTIONAL STUDIES; HALLUCINOGENS; HEMODYNAMICS; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; OCCIPITAL LOBE; PSYCHIATRIC STATUS RATING SCALES; SEROTONERGIC NEURONS; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; STREET DRUGS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84864553376     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.12.002     Document Type: Article

References (43)

1. Anderson I.M., Del-Ben C.M., McKie S., Richardson P., Williams S.R., Elliott R., Deakin J.F. Citalopram modulation of neuronal responses to aversive face emotions: a functional MRI study. Neuroreport 2007, 18:1351-1355.
2. Ashburner J. A fast diffeomorphic image registration algorithm. NeuroImage 2007, 38:95-113.
3. Attenburrow M.J., Mitter P.R., Whale R., Terao T., Cowen P.J. Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology (Berl) 2001, 155:323-326.
4. Beck A.T. A systematic investigation of depression. Compr. Psychiatry 1961, 2:163-170.
5. Booij J., Tissingh G., Winogrodzka A., Boer G.J., Stoof J.C., Wolters E.C., van Royen E.A. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur. J. Nucl. Med. 1997, 24:68-71.
6. Brevard M.E., Kulkarni P., King J.A., Ferris C.F. Imaging the neural substrates involved in the genesis of pentylenetetrazol-induced seizures. Epilepsia 2006, 47:745-754.
7. Buchert R., Thomasius R., Wilke F., Petersen K., Nebeling B., Obrocki J., Schulze O., Schmidt U., Clausen M. A voxel-based PET investigation of the long-term effects of "ecstasy" consumption on brain serotonin transporters. Am. J. Psychiatry 2004, 161:1181-1189.
8. Buchert R., Schulze O., Wilke F., Berding G., Thomasius R., Petersen K., Brenner W., Clausen M. Is correction for age necessary in SPECT or PET of the central serotonin transporter in young, healthy adults?. J. Nucl. Med. 2006, 47:38-42.
9. Chalela J.A., Alsop D.C., Gonzalez-Atavales J.B., Maldjian J.A., Kasner S.E., Detre J.A. Magnetic resonance perfusion imaging in acute ischemic stroke using continuous arterial spin labeling. Stroke 2000, 31:680-687.
10. Chang L., Grob C.S., Ernst T., Itti L., Mishkin F.S., Jose-Melchor R., Poland R.E. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a coregistered SPECT and MRI study. Psychiatry Res. 2000, 98:15-28.
11. Chen Y., Wan H.I., O'Reardon J.P., Wang D.J., Wang Z., Korczykowski M., Detre J.A. Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. Clin. Pharmacol. Ther. 2011, 89(2):251-258.
12. de Win M.M., Habraken J.B., Reneman L., van den Brink W., den Heeten G.J., Booij J. Validation of [123I]-ß-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005, 30:996-1005.
13. de Win M.M., Schilt T., Reneman L., Vervaeke H., Jager G., Dijkink S., Booij J., van den Brink W. Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. J. Psychopharmacol. 2006, 20:226-235.
14. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., Olabarriaga S.D., den Heeten G.J., van den Brink W. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008, 131:2936-2945.
15. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., Olabarriaga S.D., Ramsey N.F., Heeten G.J., van den Brink W. Neurotoxic effects of ecstasy on the thalamus. Br. J. Psychiatry 2008, 193:289-296.
16. Gevers S., van Osch M.J., Bokkers R.P., Kies D.A., Teeuwisse W.M., Majoie C.B., Hendrikse J., Nederveen A.J. Intra- and multicenter reproducibility of pulsed, continuous and pseudocontinuous arterial spin labeling methods for measuring cerebral perfusion. J. Cereb. Blood Flow Metab. 2011, 31(8):1706-1715.
17. Golay X., Hendrikse J., Lim T.C. Perfusion imaging using arterial spin labeling. Top. Magn. Reson. Imaging 2004, 15:10-27.
18. Golay X., Petersen E.T., Hui F. Pulsed star labeling of arterial regions (PULSAR): a robust regional perfusion technique for high field imaging. Magn. Reson. Med. 2005, 53:15-21.
19. Hagino H., Tabuchi E., Kurachi M., Saitoh O., Sun Y., Kondoh T., Ono T., Torii K. Effects of D2 dopamine receptor agonist and antagonist on brain activity in the rat assessed by functional magnetic resonance imaging. Brain Res. 1998, 813:367-373.
20. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J. Neurosci. 2004, 24:9553-9560.
21. Khalili-Mahani N., van Osch M.J., Baerends E., Soeter R.P., de Kam M., Zoethout R.W., Dahan A., van Buchem M.A., van Gerven J.M., Rombouts S.A. Pseudocontinuous arterial spin labeling reveals dissociable effects of morphine and alcohol on regional cerebral blood flow. J. Cereb. Blood Flow Metab. 2011, 31:1321-1333.
22. Kish S.J., Lerch J., Furukawa Y., Tong J., McCluskey T., Wilkins D., Houle S., Meyer J., Mundo E., Wilson A.A., Rusjan P.M., Saint-Cyr J.A., Guttman M., Collins D.L., Shapiro C., Warsh J.J., Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography [11C]DASB and structural brain imaging study. Brain 2010, 133:1779-1797.
23. McBean D.E., Ritchie I.M., Olverman H.J., Kelly P.A. Effects of the specific serotonin reuptake inhibitor, citalopram, upon local cerebral blood flow and glucose utilisation in the rat. Brain Res. 1999, 847:80-84.
24. McCann U.D., McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. Lancet 1998, 352:1433-1437.
25. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 2005, 30:1741-1750.
26. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (±)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 2008, 200:439-450.
27. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl) 2005, 180:680-686.
28. Ogawa S., Lee T.M., Kay A.R., Tank D.W. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:9868-9872.
29. Parsey R.V., Oquendo M.A., Simpson N.R., Ogden R.T., Van Heertum R., Arango V., Mann J.J. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT receptor binding potential measured by PET using 1A[C-11]WAY-100635. Brain Res. 2002, 954:173-182.
30. Patton J.H., Stanford M.S., Barratt E.S. Factor structure of the Barratt impulsiveness scale. J. Clin. Psychol. 1995, 51:768-774.
31. Penttila J., Syvalahti E., Hinkka S., Kuusela T., Scheinin H. The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 2001, 154:343-349.
32. Pirker W., Asenbaum S., Hauk M., Kandlhofer S., Tauscher J., Willeit M., Neumeister A., Praschak-Rieder N., Angelberger P., Brucke T. Imaging serotonin and dopamine transporters with [123I]-ß-CIT SPECT: binding kinetics and effects of normal aging. J. Nucl. Med. 2000, 41:36-44.
33. Preece M.A., Taylor M.J., Raley J., Blamire A., Sharp T., Sibson N.R. Evidence that increased 5-HT release evokes region-specific effects on blood-oxygenation level-dependent functional magnetic resonance imaging responses in the rat brain. Neuroscience 2009, 159:751-759.
34. Rao S.M., Salmeron B.J., Durgerian S., Janowiak J.A., Fischer M., Risinger R.C., Conant L.L., Stein E.A. Effects of methylphenidate on functional MRI blood-oxygen-level-dependent contrast. Am. J. Psychiatry 2000, 157:1697-1699.
35. Reneman L., Habraken J.B., Majoie C.B., Booij J., den Heeten G.J. MDMA ("ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am. J. Neuroradiol. 2000, 21:1001-1007.
36. Reneman L., Booij J., de Bruin K., Reitsma J.B., de Wolff F.A., Gunning W.B., den Heeten G.J., van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001, 358:1864-1869.
37. Rose E.J., Simonotto E., Spencer E.P., Ebmeier K.P. The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task. Psychopharmacology (Berl) 2006, 185:339-347.
38. Ryding E., et al. A new model for separation between brain dopamine and serotonin transporters in 123I-β-CIT SPECT measurements: normal values and sex and age dependence. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:1114-1118.
39. Seifritz E., Baumann P., Muller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., Holsboer-Trachsler E. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 1996, 14:253-263.
40. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br. J. Psychiatry 1999, 175:63-69.
41. Szabo Z., McCann U.D., Wilson A.A., Scheffel U., Owonikoko T., Mathews W.B., Ravert H.T., Hilton J., Dannals R.F., Ricaurte G.A. Comparison of (±)[11C]-McN5652 and [11C]-DASB as serotonin transporter radioligands under various experimental conditions. J. Nucl. Med. 2002, 43:678-692.
42. Tjandra T., Brooks J.C., Figueiredo P., Wise R., Matthews P.M., Tracey I. Quantitative assessment of the reproducibility of functional activation measured with BOLD and MR perfusion imaging: implications for clinical trial design. NeuroImage 2005, 27:393-401.
43. Wingen M., Kuypers K.P., van de Ven V., Formisano E., Ramaekers J.G. Sustained attention and serotonin: a pharmaco-fMRI study. Hum. Psychopharmacol. 2008, 23:221-230.